Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970501 · ClinicalTrials.gov registry record · Phase 2
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT01970501 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 267 participants.
The verdict
NCT01970501, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Interventions
- DRUG metoprolol succinate
- OTHER Placebo oral capsule
- DRUG bucindolol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970501
The ClinicalTrials.gov registry entry for NCT01970501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metoprolol succinate is the first listed.
NCT01970501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970501 about?
NCT01970501 is a clinical study titled "Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure". This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
What is the current status of trial NCT01970501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2014-04. Estimated completion is 2017-12-28.
What interventions are being tested in trial NCT01970501?
The interventions under investigation include: metoprolol succinate (DRUG), Placebo oral capsule (OTHER), bucindolol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01970501?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.